IM
IMNN.US Imunon Inc
- Market cap
- USD 4.08M
- P/E
- -
- P/B
- 1.56x
- ROE
- -549.8%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMNN.US undervalued?
Graham numberThe Graham number of Imunon Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imunon Inc fundamental analysis
No fundamental analysis for Imunon Inc yet.
Imunon Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that …
Full company profileImunon Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Imunon Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 500K | 500K | 500K | 500K | 500K | 500K | 500K | 125K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 500K | 500K | 500K | 500K | 500K | 500K | 500K | -720K | -718K | - | - |
| Operating Income | -20.6M | -18.5M | -21.1M | -20.6M | -18.5M | -21.0M | -24.9M | -21.0M | -19.1M | -14.7M | -14.1M |
| EBITDA | -20.3M | -19.8M | -21.2M | -16.6M | -21.3M | -20.9M | -31.7M | -19.9M | -17.9M | -13.8M | -13.4M |
| Net Income | -22.1M | -20.4M | -11.9M | -16.9M | -21.5M | -20.8M | -35.9M | -19.5M | -18.6M | -14.5M | -14.4M |
| EPS | -2,327 | -523 | -132 | -151 | -132 | -749 | -66 | -28 | -21 | -6.83 | -2.42 |
| Balance Sheet | |||||||||||
| Total Assets | 30.8M | 47.5M | 46.9M | 38.3M | 37.5M | 74.0M | 44.0M | 21.9M | 9.72M | 12.3M | 12.0M |
| Total Liabilities | 24.1M | 20.8M | 26.0M | 23.7M | 18.9M | 18.3M | 14.6M | 8.53M | 5.47M | 5.23M | 9.39M |
| Shareholders' Equity | 6.73M | 26.7M | 20.9M | 14.6M | 18.6M | 55.8M | 29.3M | 13.4M | 4.24M | 7.06M | 2.62M |
| Cash & Short-term Investments | 4.30M | 24.2M | 27.6M | 14.9M | 17.2M | 49.4M | 32.7M | 15.7M | 5.87M | 8.78M | 4.04M |
| Total Debt | 2.56M | - | 9.42M | 11.3M | 6.19M | 6.63M | 6.27M | 1.62M | 1.14M | 1.01M | 6.94M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.4M | -16.6M | -7.04M | -20.3M | -15.6M | -16.2M | -23.1M | -19.0M | -18.9M | -13.9M | -13.6M |
| Capital Expenditure | 62.5K | 38.6K | 138K | 349K | 19.1K | 312K | 268K | 452K | 29.5K | 281K | 94.5K |
| Free Cash Flow | -18.4M | -16.7M | -7.18M | -20.6M | -15.6M | -16.5M | -23.4M | -19.5M | -18.9M | -14.2M | -13.7M |
| Ratios | |||||||||||
| ROE | -327.9% | -76.4% | -57.0% | -115.7% | -115.4% | -37.2% | -122.4% | -145.8% | -438.7% | -205.3% | -549.8% |
| ROA | -71.5% | -42.9% | -25.4% | -44.0% | -57.2% | -28.0% | -81.6% | -89.0% | -191.6% | -118.0% | -120.1% |
| Net Profit Margin | -4,410.7% | -4,080.4% | -2,376.7% | -3,370.3% | -4,296.7% | -4,153.9% | -7,179.6% | -15,612.0% | - | - | - |
| Debt to Equity | 0.38x | - | 0.45x | 0.78x | 0.33x | 0.12x | 0.21x | 0.12x | 0.27x | 0.14x | 2.65x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Imunon Inc dividends
- Dividend yield
- 0.25%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 10.3K | 0.00 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 115:100 on Aug 7, 2025.
Who owns Imunon Inc
- Insiders 7.89%
- Institutions 5.94%
- Public & others 86.17%
- Shares outstanding 6.49M
- Free float 5.15M
Top funds holding IMNN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 32.5K | 0.52% | 0.00% | Sep 2026 |
| Renta 4 Delta R FI | 7.00K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.74K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.78K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding IMNN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 145K | 2.58% | -58.44% | Jun 2026 |
| Vanguard Capital Management, LLC | 47.0K | 0.84% | -2.27% | Jun 2026 |
| Riverview Capital Advisers LLC | 34.4K | 0.61% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 31.6K | 0.56% | -4.76% | Jun 2026 |
| Virtu Financial LLC | 17.5K | 0.31% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 13.3K | 0.24% | 0.00% | Jun 2026 |
| Northern Trust Corp | 10.3K | 0.18% | 0.00% | Jun 2026 |
| UBS Group AG | 5.20K | 0.09% | +804.87% | Jun 2026 |
| BlackRock Inc | 4.46K | 0.08% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.95K | 0.07% | +111.79% | Jun 2026 |
| Wells Fargo & Co | 3.34K | 0.06% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.57K | 0.03% | -48.14% | Jun 2026 |
| SBI Securities Co Ltd | 1.03K | 0.02% | 0.00% | Jun 2026 |
| Barclays PLC | 194.00 | 0.00% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 134.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Steigerwald, Gordon & Koch Inc. | 1.00 | 0.00% | 0.00% | Jun 2026 |
Imunon Inc company profile
- Company name
- Imunon Inc
- Ticker
- IMNN.US
- Exchange
- USA Stocks
- Listed since
- Mar 1, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- 997 Lenox Drive, Lawrenceville, NJ, United States, 08648
- Phone
- 609 896 9100
- Website
- imunon.com
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Imunon Inc management
6- Mr. Michael H. TardugnoExecutive Chairman · born 1951
- Dr. Stacy R. Lindborg Ph.D.President, CEO & Director · born 1970
- Dr. Douglas V. Faller M.D., Ph.D.Chief Medical Officer · born 1953
- Mr. Joshua Blacher C.P.A., M.B.A.CFO, Principal Financial Officer & Principal Accounting Officer · born 1973
- Ms. Kristin Longobardi M.B.A.Senior Vice President of Strategic Operations
- Dr. Stephen G. Machatha Ph.D.Senior Vice President of Technical Operations · born 1977